US2004214765A1PendingUtilityA1
Methods and means for inhibition of CDK4 activity
Est. expiryMay 8, 2016(expired)· nominal 20-yr term from priority
A61K 38/00A61P 43/00C07K 14/4703A61P 35/00
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
p 21 WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation, and cellular proliferation, indicative of therapeutic usefulness in treatment of tumours and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.
Claims
exact text as granted — not AI-modified1 . A method of inhibiting the activity of a G1 cdk, the method including contacting said cdk with a substance that includes a peptide of 40 amino acids or less, the peptide including the motif:
Kxxrryfzp (wherein x may be any amino acid, y and z may be hydrophobic, and each of the underlined residues may be absent or different).
2 . A method according to claim 1 wherein y or/and z is, or are independently, any one of: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine.
3 . A method according to claim 1 , wherein said peptide is a fragment of p21 or an active portion or derivative thereof.
4 . A method according to claim 1 , wherein said peptide consists of residues 16-35 of the p21 WAF1 amino acid sequence or an active portion or derivative thereof.
5 . A method according to claim 3 or claim 4 , wherein said peptide is a said active portion or a said derivative and said active portion or said derivative has at least 80% identity with p21 over a window of at least 5 amino acids.
6 . A method according to claim 1 wherein said peptide is coupled to a carrier molecule.
7 . A method according to claim 6 , wherein the carrier molecule has the sequence RQIKIWFQNRRMKWKK.
8 . A method according to claim 1 wherein the peptide binds to a G1 cyclin or a G1 cdk.
9 . An assay method for a compound with ability to modulate interaction or binding between a peptide as defined in claim 1 and a G1 cyclin and/or a G1 cdk, the method including:
(a) bringing into contact said peptide, a substance including a said cyclin or an active portion or derivative thereof, and/or a substance including a said cdk or an active portion or derivative thereof, and a test compound, under conditions wherein, in the absence of the test compound being an inhibitor of interaction or binding of said peptide and one or more of said substances, said peptide and one or more of said substances interact or bind; and
(b) determining interaction or binding between said peptide and one or more of said substances.
10 . A method according to claim 9 , wherein a compound is additionally tested for ability to modulate a p21-mediated effect on activity of a G1 cdk.
11 . A method according to claim 1 or claim 10 wherein the cdk activity includes Rb phosphorylation.
12 . A method according to claim 1 or claim 10 wherein induction of cell cycle arrest is tested.Join the waitlist — get patent alerts
Track US2004214765A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.